An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC).
Domchek, S Postel-Vinay, S Bang, Y Park, Y Alexandre, J Delord, J Italiano, A You, B Bastian, S Krebs, Matthew G
Domchek, S
Postel-Vinay, S
Bang, Y
Park, Y
Alexandre, J
Delord, J
Italiano, A
You, B
Bastian, S
Krebs, Matthew G
Citations
Altmetric:
Abstract
Description
Date
2018-02-14
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC). 2018, 78(4 Suppl): PD6-11 Cancer Res